One of the most recent families of anti-diabetic drugs is sodium-glucose cotransporter-2 (SGLT-2) inhibitors (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin, ertugliflozin, sotagliflozin, and luseogliflozin) that have improved the management of diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.